Please ensure Javascript is enabled for purposes of website accessibility

Pfizer to Market Viagra Through Roman's Telehealth Service

By Todd Campbell - Jan 23, 2020 at 10:36AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pfizer's U.S. generic drug subsidiary, Greenstone, is partnering with men's health provider Roman to provide Viagra to patients.

Pfizer (PFE 1.29%) will provide patients of Roman, a men's health subsidiary of the privately held digital health company Ro, with the only Pfizer-authorized generic version of Viagra, a blockbuster erectile dysfunction treatment.

A happy older couple sitting on a floor with travel bags.

IMAGE SOURCE: GETTY IMAGES.

Under the deal, Pfizer's U.S. generic subsidiary, Greenstone, will provide generic Viagra to Roman patients following a telehealth consultation with one of Roman's licensed physicians. This is the first time that Greenstone is collaborating with a direct-to-patient health company.

Viagra won Food and Drug Administration approval in 1998 and it grew into one of the world's best selling medications, with global sales in excess of $2 billion at their peak in 2012. Generic drugmakers, including Teva Pharmaceutical (TEVA 0.53%) and Mylan (MYL) have been marketing generic versions of the drug since 2018, but Greenstone is the only manufacturer authorized to produce pills in the same plant as Pfizer's brand name drug. In Q3, 2019, Pfizer reported global Viagra revenue of $120 million, including $20 million in the United States. 

The agreement is significant because men are 24% less likely to go to a doctor over a one-year period than women and according to the companies, only one quarter of the 30 million American men experiencing ED are getting treatment. By providing access to generic Viagra through an online doctor's visit, the companies hope to break down barriers preventing men from consulting with their doctor about ED, while also ensuring patients receive a high-quality product, as Viagra is one of the most counterfeited drugs in the world. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$53.15 (1.29%) $0.68
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$8.51 (0.53%) $0.04
Viatris Inc. Stock Quote
Viatris Inc.
MYL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.